

Bladder Cancer

CHI Formulary Treatment algorithm

Treatment algorithm- October 2023

Supporting treatment algorithms
for the clinical management of
Bladder Cancer

Figures 1 to 4 outline a comprehensive treatment algorithm on **the management of Bladder Cancer**, aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Bladder Cancer** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at <https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx>

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.




Figure 1: Management of non-muscle invasive bladder cancer

¹ Saudi Oncology society and Saudi urology association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder (2017) and NCCN bladder cancer clinical practice guidelines 2023




Figure 2: Management of muscle invasive Bladder Cancer

² Saudi Oncology society and Saudi urology association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder (2017) and NCCN bladder cancer clinical practice guidelines 2023




Figure 3: Management of metastatic urothelial carcinoma

³ Saudi Oncology society and Saudi urology association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder (2017) and NCCN bladder cancer clinical practice guidelines 2023




Figure 4: Management of Relapsed Metastatic urothelial carcinoma

⁴ Saudi Oncology society and Saudi urology association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder (2017) and NCCN bladder cancer clinical practice guidelines 2023